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plantation, Alsina et al. and Donato et al. each report onwell-
sized prospective studies of allogeneic hematopoietic stem
cell transplantation (allo-HCT) with reduced intensity in
patients with multiple myeloma [1,2]. In the Alsina trial, the
use of lenalidomide maintenance therapy after allo-HCT is
evaluated for its contribution to additional disease control,
primarily as an immunomodulatory agent, and to allow time
for the graft-versus-myeloma effect to become established.
In the second study, a somewhat larger population of both
newly diagnosed patients and salvage patients demonstrates
that allo-HCT for myeloma can lead to sustained remission.
However, acute graft-versus-host disease (aGVHD) was sig-
niﬁcantly deleterious to overall survival and progression-free
survival in this trial, whereas chronic graft-versus-host dis-
ease (cGVHD)was favorable, suggesting an important role for
the graft-versus-myeloma effect.
In theﬁrst trial, a lowerdose of lenalidomide after allo-HCT
proved feasible, with lenalidomide initiated approximately
100 days after allo-HCT and at a 10 mg daily dose of lenali-
domide delivered 3 weeks out of 4. Although lenalidomide
after allo-HCTwas associated with a 38% incidence of aGVHD,
the survival outcomes observed were encouraging in thishigh-risk population and certainly warrant further study for
this approach, especially given theworse outcomes seenwith
other studies using higher doses and different schedules [3].
The second study also demonstrated encouraging overall
survival at 5 years of 59%; however, the 5-year overall survival
for patients who received transplantation as salvage was
substantially lower than in those who received it as consoli-
dation, after autologous transplantation during initial treat-
ment. Interestingly, univariate analysis conﬁrmed that in
patients receiving allogeneic transplantation as salvage,
advanced disease status before allogeneic stem cell trans-
plantation, increased number of prior autologous trans-
plantations, use of nonmyeloablative regimen, and presence
of aGVHD were adverse, versus response to allogeneic trans-
plantation and presence of cGVHD, with each of the latter
associated with a favorable impact on overall survival. The
positive effect of cGVHD was noteworthy; intriguingly, donor
type (be it unrelated or related), as well as cytogenetics and
age, were otherwise not signiﬁcant predictors of outcome.
Recognizing that the numbers in these studies remain rela-
tively small and selected, and thus these observations have to
be treated with some caution, the observations are nonethe-
less provocative, not least as they underscore the importance
of an effective immunologic platform in disease control to
achieve improved overall survival.
In aggregate, both studies also provide important infor-
mation to challenge a strongly held view in the ﬁeld of
myeloma that there is little or no role for allo-HCT [4,5]. Each
suggest a rationale for further prospective studies, and in
particular, they lend support to the further integration of
novel therapies into allo-HCT. Speciﬁcally, and as mentioned
above, other trials have shown that lenalidomide given at a
ﬁxed dose earlier in the allogeneic setting is associated with
unacceptable toxicity, in particular aGVHD [3]. The study by
Alsina et al. demonstrates that a 3-week on and 1-week off
schedule deployed later after transplantation, and similar to
that used in the postautologous setting, creates a major
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proteasome inhibition have been associated with improved
outcomes, and bortezomib currently provides an exciting
opportunity for more selective antimyeloma effect with less
aGVHD, so providing a strong rationale for using proteasome
inhibition as a maintenance strategy either alone or in
combination [6]. Prospective studies of this particular
approach and using oral proteasome inhibitors are, there-
fore, planned by a uniﬁed team of investigators across
various groups in the United States, including the Alliance
and the Clinical Trials Network.
Further, the integration of 3 drug initial treatment strate-
gies has generated unprecedented and very high levels of
overall response (regardless of adverse cytogenetics), pro-
viding a vital next step in considering the overall treatment
approach in the allogeneic setting [7,8]. These combinations,
together with less toxic conditioning regimens, as well
as improved post-transplantation strategies, suggest that
selected patients (both with HLA-identical sibling and unre-
lateddonors)might reasonably be candidates forparticipation
in prospective, multicenter studies.
One of the major dilemmas facing clinicians in exploring
the allogeneic approach is the remarkable success observed
with not only ﬁrst-generation novel agents in the manage-
ment of this heterogeneous and profoundly challenging
disease, but also the impact of second- and third-generation
proteasome inhibitors and immunomodulators, respectively,
as well asmonoclonal antibodies in particular, and nowother
small molecules, such as deacetylase inhibitors [9]. The
advent of novel and highly promising immunotherapeutic
strategies (including vaccines and check point inhibitors)
may allow for additional leverage of the allogeneic platform
[10]. Therefore, strategies aimed at reducing GVHD and
improving the tolerability of this approach need to remain
paramount, with the integration of additional novel treat-
ment strategies to further improve patient outcome all the
more vital.
Regardless of these caveats, both of these studies clearly
inform future approaches to allogeneic transplantation and
suggest that this modality can bemore successfully exploited
in myeloma. Hopefully, a niche for allo-HCT can thus beestablished for our patients, as part of a much needed and
broadly based therapeutic armamentarium against this
otherwise incurable disease.
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